2016 ASCO Annual Meeting - ASCO


Powered by SmugMug Log In
Helen MacKay, MBChB, BSc., MRCP, MD, presenting abstract LBA5503, OV21/PETROC: A Randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) vs. intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC) during Gynecologic Cancer Oral Abstract Session

Helen MacKay, MBChB, BSc., MRCP, MD, presenting abstract LBA5503, OV21/PETROC: A Randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) vs. intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC) during Gynecologic Cancer Oral Abstract Session

Chicago, IL - 2016 ASCO Annual Meeting - Helen MacKay, MBChB, BSc., MRCP, MD, presenting abstract LBA5503, OV21/PETROC: A Randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) vs. intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC) during Gynecologic Cancer Oral Abstract Session at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Sunday, June 5, 2016. Over 30,000 physicians, researchers, and healthcare professionals from over 100 countries are attending the 52nd Annual Meeting which is being held at the McCormick Place convention center. The Annual Meeting highlights the latest findings in all major areas of oncology from basic through clinical and epidemiological studies. Photo by © ASCO/David Eulitt 2016 Technical Questions: todd@medmeetingimages.com; ASCO Contact: photos@asco.org